The Amorphous Solid Dispersion of Chrysin in Plasdone® S630 Demonstrates Improved Oral Bioavailability and Antihyperlipidemic Performance in Rats
Pharmaceutics · 24.09.2023 · 15 (10) · 2378
DOI: 10.3390/pharmaceutics15102378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 24.09.2023. Verfasst von Chenhui Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nantong University, 19 Qixiu Road, Nantong 226001, China. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Funding of Nantong City, College Student Innovation Training Program of Nantong University, Research Program of Guangdong Provincial Key Laboratory of Microecological Preparations.
Abstract (Originalsprache)
Chrysin is a flavonoid with various biological activities. However, its low water solubility and strong metabolism render its oral bioavailability rather poor. This study aimed to develop a stable solid dispersion formulation of chrysin to improve the dissolution of chrysin, so as to increase its oral bioavailability and improve its antihyperlipidemic activities. A solid dispersion of chrysin was prepared using a solvent evaporation method, with Plasdone® S630 as the hydrophilic carrier. The formulations were characterized via X-ray diffraction, in vitro dissolution studies, and stability studies. An in-situ perfusion model was used to evaluate the absorption rates. Plasma pharmacokinetics and antihyperlipidemic performance after the oral administration of the chrysin formulations were investigated in rats. It was found that the solid dispersion of chrysin prepared using the drug–polymer mass ratio of 1:6 can form the optimized formulation. X-ray diffraction results showed that the chrysin was in an amorphous state in this optimized formulation. The cumulative release percentage of the optimized solid dispersion of chrysin at pH 1.2 and pH 6.8 was elevated to above 90% within 24 h, indicating that the formulation could enhance the dissolution rates of chrysin. Stability studies showed that the optimized formulation presented acceptable long-term storage stability, but it was susceptible to high temperature and humidity. The solid dispersion of chrysin showed higher absorption rates in the in-situ perfusion model. Pharmacokinetic studies revealed that Cmax and AUC after the intragastric administration of solid dispersion of chrysin were appreciably higher than those resulting from chrysin suspension. The oral bioavailability of the solid dispersion of chrysin was 41 times higher than that of chrysin suspension. Pharmacological studies suggested that the solid dispersion of chrysin was more powerful than chrysin raw material in improving biochemical indicators in the hyperlipidemic model in rats. This study reveals the potential use of a novel oral formulation of chrysin to reduce the currently required high dose.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Nantong University, 19 Qixiu Road, Nantong 226001, China.
- School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.
- Shenzhen Wanhe Pharmaceutical Company & Guangdong Provincial Key Laboratory of Microecological Preparations, 7 Huitong Road, Shenzhen 518107, China.
Förderung
- Science and Technology Funding of Nantong City
- College Student Innovation Training Program of Nantong University
- Research Program of Guangdong Provincial Key Laboratory of Microecological Preparations
- Initiation Project of Shenzhen Engineering Research Center for New Oral Solid Formulations
Zitieren
APA
Wang, C., Liu, X., Zhao, R., Yang, M., Liu, W., Dai, Q., Bao, X., Chen, Y., & Ma, J. (2023). The Amorphous Solid Dispersion of Chrysin in Plasdone® S630 Demonstrates Improved Oral Bioavailability and Antihyperlipidemic Performance in Rats. Pharmaceutics, 15(10), 2378. https://doi.org/10.3390/pharmaceutics15102378
Vancouver
Wang C, Liu X, Zhao R, Yang M, Liu W, Dai Q, et al. The Amorphous Solid Dispersion of Chrysin in Plasdone® S630 Demonstrates Improved Oral Bioavailability and Antihyperlipidemic Performance in Rats. Pharmaceutics. 2023;15(10):2378. doi:10.3390/pharmaceutics15102378
BibTeX
@article{Wang2023,
author = {Wang, Chenhui and Liu, Xiaowei and Zhao, Ruihan and Yang, Meiqing and Liu, Wenqian and Dai, Qiuyang and Bao, Xiaofeng and Chen, Yong and Ma, Jun},
title = {The Amorphous Solid Dispersion of Chrysin in Plasdone® S630 Demonstrates Improved Oral Bioavailability and Antihyperlipidemic Performance in Rats},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {10},
pages = {2378},
doi = {10.3390/pharmaceutics15102378}
}
EUVIMED